TGFB1 and breast cancer: Interestingly, AML but not breast cancer patients showed significantly increased blood plasma levels of TGF-β (Figure 3), which suggests that in breast (solid) tumours TGF-β remains within tumour microenvironment, while in AML it is secreted into the blood thus having the opportunity to systemically act on AML cells in circulation.